Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Evogene Q3 EPS $(0.31) Beats $(0.41) Estimate, Sales $312.000K Miss $650.000K Estimate

Author: Benzinga Newsdesk | November 20, 2025 07:30am
Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.41) by 24.39 percent. This is a 76.34 percent increase over losses of $(1.31) per share from the same period last year. The company reported quarterly sales of $312.000 thousand which missed the analyst consensus estimate of $650.000 thousand by 52.00 percent. This is a 82.63 percent decrease over sales of $1.796 million the same period last year.

Posted In: EVGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist